Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Market Research

Preparing for the Horizons: Perspectives on Psychedelics Event in New York

Horizons: Perspectives on Psychedelics stands as a beacon for those intrigued by the enigmatic world of psychedelic research and culture. As Horizons approaches its 16th year, this seminal event promises to unfold over three enlightening days, from May 9-11, 2024, at the prestigious New York Academy of Medicine. This year’s gathering is not just an…

Market Research

atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study

atai Life Sciences, trading under NASDAQ:ATAI and ETR:9VC, recently announced the encouraging findings from a study conducted by its investee, Beckley Psytech, on a pioneering DMT formulation, BPL-003, for individuals struggling with treatment-resistant depression. During this open-label Phase 2a investigation, a select group of patients received a single dose of BPL-003. This novel, synthetic formulation…

Press

Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression

OXFORD, United Kingdom–(BUSINESS WIRE)– Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced positive initial findings from its Phase IIa clinical study (NCT05660642) of BPL-003 for Treatment Resistant Depression (TRD). BPL-003 is Beckley Psytech’s novel, synthetic,…

Press

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

CAMBRIDGE, Mass., March 26, 2024–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31,…

Optimi-Health Press

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is thrilled to announce it has entered an international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv…

PharmAla-Biotech Press

PharmAla Biotech Signs Sale Agreement with Numinus

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI,…

Psyence Press

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence” or the “Company“) (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the “Transaction“), Psyence is pleased to announce that the conditions to implement the Transaction have been met and that the Transaction has closed. Psyence has built…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.